AMOYTOP(SH:688278) Xin Lang Cai Jing·2026-01-12 06:05Group 1 - The core point of the news is that TeBao Bio experienced a 5.2% decline in stock price, reaching 76.40 yuan per share, with a trading volume of 251 million yuan and a turnover rate of 0.79%, resulting in a total market capitalization of 31.186 billion yuan [1] - TeBao Bio, established on August 7, 1996, is located in Xiamen, Fujian Province, and was listed on January 17, 2020. The company specializes in the research, production, and sales of recombinant proteins and long-acting modified drugs [1] - The main revenue composition of TeBao Bio includes 86.85% from antiviral drugs, 12.87% from blood/tumor drugs, and 0.27% from other supplementary products [1] Group 2 - From the perspective of fund holdings, HSBC Jintrust Fund has one fund heavily invested in TeBao Bio. The HSBC Jintrust Medical Pioneer Mixed A Fund (012358) reduced its holdings by 63,200 shares in the third quarter, now holding 160,200 shares, which accounts for 3.96% of the fund's net value, ranking as the ninth largest holding [2] - The HSBC Jintrust Medical Pioneer Mixed A Fund (012358) was established on July 12, 2021, with a current size of 170 million yuan. Year-to-date returns are 12.33%, ranking 269 out of 9,012 in its category; the one-year return is 86.56%, ranking 323 out of 8,157; and since inception, it has a loss of 15.62% [2] - The fund manager of HSBC Jintrust Medical Pioneer Mixed A Fund is Li Bokan, who has been in the position for 1 year and 13 days, with total assets under management of 340 million yuan. The best fund return during his tenure is 76.34%, while the worst is 75.58% [2]